Drug firm Zydus Cadila today said it has received final approval from the United States Food and Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base).
It (Tamoxifen Citrate Tablets USP) will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad, the company said in a BSE filing.
The drug is indicated to treat breast cancer, the company said in the filing.
The group now has more than 165 approvals, it added.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.